{"filing":{"accession_number":"0001668397-26-000023","cik":"0001668397","ticker":"MEDP","company_name":"Medpace Holdings, Inc.","form":"8-K","filing_date":"2026-07-22","report_date":null,"primary_document":"medp-20260722.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1668397/000166839726000023/medp-20260722.htm"},"events":[{"id":19553,"run_id":17587,"accession_number":"0001668397-26-000023","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"Medpace issued a press release on July 22, 2026 announcing financial results for the three and six months ended June 30, 2026, disclosing Q2 2026 revenue of $707.3 million (17.2% growth), GAAP net income of $121.4 million ($4.25 per diluted share), and full-year 2026 guidance. This is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02, materially affecting investor assessment of the company's financial performance and outlook.","company_name":"Medpace Holdings, Inc.","ticker":"MEDP","filing_date":"2026-07-22","form":"8-K","submitted_at":null,"items":[{"id":18666,"accession_number":"0001668397-26-000023","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Medpace issued a press release on July 22, 2026 announcing financial results for the three and six months ended June 30, 2026, disclosing Q2 2026 revenue of $707.3 million (17.2% growth), GAAP net income of $121.4 million ($4.25 per diluted share), and full-year 2026 guidance. This is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02, materially affecting investor assessment of the company's financial performance and outlook.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-22T20:20:07.096586+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":18666,"accession_number":"0001668397-26-000023","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Medpace issued a press release on July 22, 2026 announcing financial results for the three and six months ended June 30, 2026, disclosing Q2 2026 revenue of $707.3 million (17.2% growth), GAAP net income of $121.4 million ($4.25 per diluted share), and full-year 2026 guidance. This is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02, materially affecting investor assessment of the company's financial performance and outlook.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-22T20:20:07.096586+00:00","company_name":"Medpace Holdings, Inc.","ticker":"MEDP","filing_date":"2026-07-22"}]}